Your session is about to expire
← Back to Search
Liquid Embolic Agent
PHIL in the Treatment of Intracranial dAVF. (PHIL dAVF Trial)
N/A
Waitlist Available
Led By J Mocco, MD
Research Sponsored by Microvention-Terumo, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 days
Awards & highlights
No Placebo-Only Group
Summary
This trial uses a special liquid to treat patients with abnormal blood vessel connections in the brain, who have few safe treatment options. The liquid hardens and blocks these abnormal vessels, stopping the problematic blood flow.
Eligible Conditions
- Arteriovenous Malformations
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ during the procedure
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~during the procedure
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Subjects with neurological death or ipsilateral stroke
Secondary study objectives
Technical events during the PHIL embolization procedure(s)
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: dAVF treatmentExperimental Treatment1 Intervention
PHIL® Liquid Embolic System
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PHIL® Liquid Embolic System
2018
N/A
~70
Find a Location
Who is running the clinical trial?
Microvention-Terumo, Inc.Lead Sponsor
31 Previous Clinical Trials
6,937 Total Patients Enrolled
1 Trials studying Arteriovenous Malformations
20 Patients Enrolled for Arteriovenous Malformations
J Mocco, MDPrincipal InvestigatorMt. Sinai
4 Previous Clinical Trials
1,275 Total Patients Enrolled
Alan Boulos, MDPrincipal InvestigatorAlbany Medical College